Idelalisib With Bendamustine and Rituximab Superior to Bendamustine and Rituximab alone for Relapsed/Refractory CLLDecember 10, 2015
For patients with relapsed/refractory CLL, the addition of idelalisib to bendamustine and rituximab can prove more beneficial than the latter two drugs alone, recent study data suggest.
A recent study examined the direct and indirect costs for patients with relapsed or refractory multiple myeloma.
Results of a phase 3 randomized trial support high intensity conditioning with myeloablative regimens prior to allogeneic stem cell transplantation as standard of care for patients with acute myeloid leukemia.
Treatment with venetoclax monotherapy may be a viable option for some high-risk patients with relapsed/refractory chronic lymphocytic leukemia.
Overall survival rates for Medicare beneficiaries with myelodysplastic syndrome (MDS) showed little difference related to disease-related costs, according to data presented at the 2015 ASH Annual Meeting in Florida.
A PET-guided approach may reduce the need for additional radiotherapy in some patients with advanced classical Hodgkin lymphoma.
In the first clinical trial of an anti-B-cell maturation antigen chimeric antigen receptor (CAR-BCMA), a strong anti-myeloma response was observed.
PET deemed safe for use after two cycles of BEACOPPesc chemotherapy for advanced stage Hodgkin lymphoma, according to a recent study.
The high cost of for first-line oral targeted therapies for chronic lymphocytic leukemia needs to be addressed, based on model data examining CLL prevalence and patient affordability.
Immunophenotypic expression profiles can provide a tool to discriminate cohorts of young patients with acute myeloid leukemia (AML) that have a high relapse probability.
An oral formulation of azacitidine was safe and clinically active in patients with acute myeloid leukemia (AML), according to results presented at the 57th American Society of Hematology Annual Meeting.
For patients with refractory acute myeloid leukemia (AML), employment of allogeneic stem cell transplantation may be a valid treatment strategy.
Arsenic trioxide can lower relapse rates in first-line treatment of standard risk acute promyelocytic leukemia (APL), but proper administration is required.
For patients with chronic phase chronic myeloid leukemia (CP-CML) and the T315I mutation, ponatinib treatment may offer longer overall survival.
Although a fourth chemotherapy course may benefit younger patients with poor-risk acute myeloid leukemia, those with good and standard risk demonstrated little survival benefit from the additional course.
Addition of Midostaurin Significantly Improved Event-Free and Overall Survival in Some Patients With Acute Myeloid LeukemiaDecember 06, 2015
The addition of midostaurin, a multi-target protein kinase inhibitor, to to standard chemotherapy for AML has been associated with increased survival.
Continuous antibiotic treatment can reduce infections in young patients with acute lymphoblastic leukemia (ALL).
Non-Hispanic children undergoing treatment for newly diagnosed acute lymphoblastic leukemia reported higher rates of fractures and opportunistic infections, according to new study data.
Spliceosomal-mutant leukemias displayed greater sensitivity to pharmacologic modulation of splicing than their wildtype counterparts.
A new randomized study has evaluated the addition of rituximab to the pediatric-inspired GRAALL protocol for adults with acute lymphoblastic leukemia.
High Remission Rate Seen With Arsenic Trioxide Consolidation for Children With Acute Promyelocytic LeukemiaDecember 06, 2015
Increased rates of event-free surviva were seen with lthe use of arsenic trioxide consolidation for children newly diagnosed with acute promyelocytic leukemia (APL).
TARC levels correlated with PET-normalization in certain patients with Hodgkin lymphoma treated with brentuximab vedotin, a study indicates.
Single-agent clofarabine is was effective for older patients with newly diagnosed acute myeloid leukemia than standard therapy combined with daunorubicin and cytarabine.
A presentation during the 57th American Society of Hematology (ASH) Annual Meeting examined the pros and cons of value-based purchasing.
A study has reaffirmed the importance of genetically defined PD-1 mediated immune evasion for patients with Hodgkin lymphoma.
Nearly 25 percent of patients with chronic myeloid leukemia (CML) undergoing treatment with tyrosine kinase inhibitors are vulnerable to a a "withdrawal syndrome," a recent study reported.
Research indicates that adjustment of imatinib doses based on therapeutic drug monitoring can result in higher rates of major molecular response in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.
Treatment with high-dose methotrexate was linked to significantly higher rates of disease-free survival in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL), according to results from a recent phase 3 trial.
Subjective over-reporting of 6-mercaptopurine (6MP) intake during maintenance therapy for childhood acute lymphoblastic leukemia is common, according to a new cohort study.
Inotuzumab ozogamicin combined with low-intensity mini-hyper-CVD chemotherapy has demonstrated encouraging results in older patients with acute lymphoblastic leukemia, according to data from an ongoing study.
Sign Up for Free e-newsletters
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Breast Cancer Deaths Decrease Sharply Since 2000
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|